Zydus receives EIR for the oncology injectable manufacturing facility in SEZ1, Ahmedabad

Zydus Lifesciences Ltd has received the Establishment Inspection Report (EIR) from the USFDA for a GMP follow-up inspection conducted at its oncology injectable facility located at SEZ1, Ahmedabad from 9th to 18th June 2025. The EIR has classified the facility as Voluntary Action Indicated (VAI). The facility was earlier classified as an Official Action Indicated (OAI) in June 2024 which is now revised to Voluntary Action Indicated (VAI).

Shares of Zydus Lifesciences Limited was last trading in BSE at Rs. 1037.00 as compared to the previous close of Rs. 1047.90. The total number of shares traded during the day was 30673 in over 2708 trades.

The stock hit an intraday high of Rs. 1059.00 and intraday low of 1034.10. The net turnover during the day was Rs. 32034616.00.

Source : Equity Bulls

Keywords

ZydusLifesciences INE010B01027 Pharmaceuticals USFDA EIR GMP FollowupInspection Oncology InjectableFacility